Our Leadership Team
|
Mark Midei, MD
Chief Medical Officer As a Johns Hopkins trained physician, cardiologist, and faculty member, Mark has had a 28-year clinical career in interventional cardiology, and electrophysiology research. He is the author of more than 100 original peer-reviewed scientific publications and book chapters.
Mark is currently a biotechnology executive with contemporary experience in all phases of drug development. He has provided pharmaceutical industry executive leadership as the Chief Medical Officer in two companies, consultation for clinical device and drug development (Phases I-IV) and medical business development support. His services have included clinical-regulatory strategy planning, intellectual property protection, clinical trial design and implementation, site selection and screening, major regulatory filings and meeting attendance at the US FDA, the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Therapeutic areas of expertise include neurodegeneration, metabolic therapies for hypertrophic cardiomyopathy, anticoagulants, cardiac anti-arrhythmics, gastrointestinal motility disorders, and rare mitochondrial diseases. |